CSPC Baike (Shandong) Biopharmaceutical
Clinical trials sponsored by CSPC Baike (Shandong) Biopharmaceutical, explained in plain language.
Pharmaceutical subsidiary of CSPC Group, developing biologics.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Healthy volunteers needed to test new injection method for experimental drug Results expected Oct 2026 (estimated)
-
New hope for stuffy noses: experimental drug targets nasal polyps
Disease control Not yet recruitingThis study tests an investigational drug called CM326 in 212 adults with chronic sinusitis and nasal polyps. Participants will receive either CM326 or a placebo for 24 weeks, followed by an open-label period. The goal is to see if the drug shrinks polyps and eases congestion.
Phase 3 • Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Healthy volunteers needed to test new injection method for experimental drug
Knowledge-focused Not yet recruitingThis study tests an experimental drug called CM326 in 192 healthy men aged 18 to 55. The goal is to see how the drug moves through the body and if it is safe when given through different injection devices. Participants will receive a single shot and be monitored for side effects …
Phase 1 • Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC